U.S. FDA Inspection of the Company's Manufacturing Facility at Pithampur Unit-2

Lupin Ltd has announced that U.S. FDA inspected Lupin's Pithampur Unit-2 manufacturing facility from March 21 to March 29, 2023. The inspection closed with issuance of a Form-483 with ten observations.

The company is addressing the observations comprehensively and will work with the U.S. FDA to resolve these issues at the earliest. The company upholds quality and compliance with utmost importance across all its facilities.

Shares of Lupin Limited was last trading in BSE at Rs. 652.45 as compared to the previous close of Rs. 644.20. The total number of shares traded during the day was 27593 in over 2330 trades.

The stock hit an intraday high of Rs. 658.50 and intraday low of 642.05. The net turnover during the day was Rs. 18006056.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals PithamputUnit2 Inspection USFDA Form483 10Observations